The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Phase 2 Completed NCT05772520

Summary

This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 2 doses of TLL018 as therapy in approximately 90 participants with moderate-to-severe PP.

Proportion of Participants Achieving PASI-75 (FAS)

Week12 · Participants

Proportion of Participants Achieving PASI 75 (PPS)

Week12 · Participants

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab i — UCB Biopharma SRL
• A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoria — Janssen Pharmaceutical K.K.
• A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoria — Janssen Research & Development, LLC
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects Wi — UCB Biopharma SRL
• A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With A — UCB Biopharma SRL
• A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis — AbbVie

All trials